Organon Remeron Phase IV trial to look at somnolence in dose-response study of antidepressant.
Executive Summary
ORGANON REMERON PHASE IV TRIAL TO EXAMINE SOMNOLENCE in a dose-response trial, according to FDA's June 14 approval letter for Remeron (mirtazapine). Organon has agreed to conduct "a fixed dose response/somnolence study that will explore dose response for both antidepressant effectiveness and for somnolence," the letter states. "We also note your commitment to initiate this study in early 1997 and to complete this study by mid-1998." Remeron is the first alpha-2 receptor antagonist antidepressant approved in the U.S. ("The Pink Sheet" June 17, T&G-1).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth